Volume 19, Number 5—May 2013
Dispatch
Campylobacter coli Outbreak in Men Who Have Sex with Men, Quebec, Canada, 2010–2011
Table 2
Antimicrobial drug susceptibility results for Campylobacter coli pulsovar 1 isolates from 10 patients, Montreal, Quebec, Canada, 2010–2011*
Antimicrobial agent† | MIC (mg/L) | Interpretation |
---|---|---|
Erythromycin | 2–4 | S |
Azithromycin | 0.25–0.5 | S |
Tetracycline | 128–256 | R |
Ciprofloxacin | >32 | R |
Nalidixic acid | >256 | R |
Ampicillin | 2–4 | S |
Gentamicin | 0.5–1 | S |
Cefotaxime | >32 | R |
Imipenem | 0.06–0.12 | S |
Clindamycin | 0.25–0.5 | S |
Chloramphenicol | 2–4 | S |
Tigecycline | ≤0.015 | NA |
β-lactamase‡ | Negative | – |
*S, susceptible; R, resistant; NA, not available; –, not applicable.
†The susceptibility and resistance breakpoints were Clinical and Laboratory Standards Institute (CLSI) Campylobacter breakpoints for erythromycin, tetracycline and ciprofloxacin (10), National Antimicrobial Resistance Monitoring System Campylobacter breakpoints for azithromycin and clindamycin (11), no breakpoints available for tigecycline and CLSI Enterobacteriaceae breakpoints for the 6 other antimicrobial agents (12).
‡β-lactamase susceptibility was determined as described (9).
References
- Allos BM, Blaser MJ. Campylobacter jejuni and related species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 7th ed. Philadelphia: Elsevier Churchill Livingston; 2010. p. 2793–802.
- Blaser MJ, Engberg J. Clinical aspects of Campylobacter jejuni and Campylobacter coli infections. In: Nachamkin I, Szymanski CM, Blaser MJ, editors. Campylobacter, 3rd ed. Washington (DC): American Society for Microbiology; 2008. p. 99–121.
- Fitzgerald C, Nachamkin I. Campylobacter and Arcobacter. In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW, editors. Manual of clinical microbiology, 10th ed. Washington (DC): American Society for Microbiology; 2011. p. 885–99.
- Gallay A, De Valk H, Cournot M, Ladeuil B, Hemery C, Castor C, A large multi-pathogen waterbone community outbreak linked to faecal contamination of a groundwater system, France, 2000. Clin Microbiol Infect. 2006;12:561–70. DOIPubMedGoogle Scholar
- Wardak S, Sadkowska-Todys M. The first report on Campylobacter coli family outbreak detected in Poland in 2006. Euro Surveill. 2008;13:8052 .PubMedGoogle Scholar
- Hill JE, Paccagnella A, Law K, Melito PL, Woodward DL, Price L, Identification of Campylobacter spp. and discrimination from Helicobacter and Arcobacter spp. by direct sequencing of PCR-amplified cpn60 sequences and comparison to cpnDB, a chaperonin reference sequence database. J Med Microbiol. 2006;55:393–9. DOIPubMedGoogle Scholar
- Hunter SB, Vauterin P, Lambert-Fair MA, Van Duyne MS, Kubota K, Graves L, Establishment of a universal size standard strain for use with the PulseNet standardized pulsed-field gel electrophoresis protocols: converting the national databases to the new size standard. J Clin Microbiol. 2005;43:1045–50. DOIPubMedGoogle Scholar
- Gaudreau C, Girouard Y, Gilbert H, Gagnon J, Bekal S. Comparison of disk diffusion and agar dilution methods for erythromycin, ciprofloxacin and tetracycline susceptibility testing of Campylobacter coli and for tetracycline for Campylobacter jejuni subsp. jejuni. Antimicrob Agents Chemother. 2008;52:4475–7. DOIPubMedGoogle Scholar
- Gaudreau C, Michaud S. Cluster of erythromycin- and ciprofloxacin-resistant Campylobacter jejuni subsp. jejuni from 1999 to 2001 in men who have sex with men, Québec, Canada. Clin Infect Dis. 2003;37:131–6. DOIPubMedGoogle Scholar
- Gaudreau C, Bruneau A, Ismaïl J. Outbreak of Shigella flexneri and Shigella sonnei enterocolitis in men who have sex with men, Québec, 1999 to 2001. Can Commun Dis Rep. 2005;31:85–90 .PubMedGoogle Scholar
- Gaudreau C, Ratnayake R, Pilon PA, Gagnon S, Roger M, Levesque S. Ciprofloxacin-resistant Shigella sonnei among men who have sex with men, Canada, 2010. Emerg Infect Dis. 2011;17:1747–50. DOIPubMedGoogle Scholar